RxDoctor Payments DataLook up a doctor →

John King, MD

Interventional Cardiology · Columbus, MSNPI 1861505448

Payments from drug & device makers

$74,157in general payments, 2019–2025

Across 698 payments — averaging $106.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$52K
  • Penumbra, Inc.$10K
  • Boston Scientific$2K
  • Novartis$1K
  • AstraZeneca$1K
  • Medtronic$928
  • plus $7K from 35 others

What the payments were for

  • Speaking & faculty fees$8,40011%
  • Travel & lodging$3781%
  • Food & beverage$12,89617%
  • Education$1500%
  • Other$52,33371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,157 in reported general payments places this provider in the 80th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$2,028,512
Medicare patients
1,713
Services billed
18,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$99,481
EntrestoSacubitril/Valsartan120$89,939
XareltoRivaroxaban142$88,432
Repatha SureclickEvolocumab40$28,054
JardianceEmpagliflozin26$14,775
BrilintaTicagrelor28$13,011
Praluent PenAlirocumab16$10,799
FarxigaDapagliflozin Propanediol12$5,888
NexlizetBempedoic Acid/Ezetimibe12$4,704
Metoprolol Succinate199$2,116
Ezetimibe74$1,895
Ranolazine ErRanolazine44$1,557
ClopidogrelClopidogrel Bisulfate261$1,401
Atorvastatin Calcium158$1,171
Rosuvastatin Calcium121$936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$308$99,481142 claims
NovartisEntresto$1,329$89,939120 claims
Johnson & JohnsonXarelto$890$88,432142 claims
AstraZenecaBrilinta, Farxiga$1,108$18,89940 claims
Boehringer IngelheimJardiance$593$14,77526 claims
Esperion Therapeutics, Inc.Nexlizet$173$4,70412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →